Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
0% citation coverage
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Intelligence Snapshot
Executive Summary
Pfizer's berobenatide (formerly MET097) demonstrated continuous weight loss through 28 weeks with monthly subcutaneous dosing in the VESPER-3 Phase 2b trial, showing no plateau at the data cutoff.
Key Insights
-
The ultra-long-acting GLP-1 receptor agonist was acquired via the Metsera acquisition and…
The ultra-long-acting GLP-1 receptor agonist was acquired via the Metsera acquisition and is now Pfizer's lead obesity asset after the company halted development of the oral danuglipron program in April 2025.
-
Monthly dosing could differentiate berobenatide from weekly competitors such as Novo…
Monthly dosing could differentiate berobenatide from weekly competitors such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, potentially capturing patient preference for less frequent injections.
-
Phase 3 planning is underway; BD teams and investors should watch for catalyst dates…
Phase 3 planning is underway; BD teams and investors should watch for catalyst dates including the formal Phase 3 start and subsequent regulatory milestones.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
Pfizer's berobenatide (formerly MET097) demonstrated continuous weight loss through 28 weeks with monthly subcutaneous dosing in the VESPER-3 Phase 2b trial, showing no plateau at the data cutoff.
Key Questions
- Why did Pfizer stop the weight loss pill?
- When will the Pfizer weight loss pill be available?
- What is MET097?
- What is the VESPER-3 trial?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for berobenatide.
Unlock full calendar →Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents7 sections
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's monthly GLP-1 RA berobenatide, acquired from Metsera, shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for obesity, with berobenatide most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key takeaways
- Pfizer's berobenatide (formerly MET097) demonstrated continuous weight loss through 28 weeks with monthly subcutaneous dosing in the VESPER-3 Phase 2b trial, showing no plateau at the data cutoff.
- The ultra-long-acting GLP-1 receptor agonist was acquired via the Metsera acquisition and is now Pfizer's lead obesity asset after the company halted development of the oral danuglipron program in April 2025.
- Monthly dosing could differentiate berobenatide from weekly competitors such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, potentially capturing patient preference for less frequent injections.
- Phase 3 planning is underway; BD teams and investors should watch for catalyst dates including the formal Phase 3 start and subsequent regulatory milestones.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Pfizer and Metsera reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
VESPER-3 trial: efficacy and safety data
The VESPER-3 Phase 2b trial evaluated monthly subcutaneous dosing of berobenatide in adults with obesity or overweight who had at least one weight-related comorbidity. The primary efficacy endpoint was percent weight loss from baseline at week 28. According to detailed data published by STAT News, the drug produced strong and continuous weight loss with no plateau observed at the 28-week mark, suggesting patients could continue to lose weight with extended treatment. The safety profile was consistent with the GLP-1 class, with gastrointestinal adverse events being the most commonly reported. Pfizer presented the full dataset at a medical meeting and confirmed the drug helped patients lose 12.3% of their body weight versus placebo after 28 weeks, as reported by the Wall Street Journal. The company stated that the data show "strong and continuous weight loss after switching to monthly dosing, with no plateau observed at week 28," per the company's press release.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for obesity. Expect implications for pricing, access, and launch sequencing.
Strategic implications for pharma BD and investors
Berobenatide's monthly dosing advantage could reshape patient preference and physician adoption dynamics in a market currently dominated by weekly GLP-1 injections. Pfizer's obesity pipeline now hinges entirely on this asset after the company shelved danuglipron in April 2025 following a signal of possible liver injury in a Phase 2 trial participant, as reported by the Associated Press. The competitive landscape remains intense: Novo Nordisk markets weekly semaglutide (Wegovy), Eli Lilly sells weekly tirzepatide (Zepbound), and a host of oral and injectable candidates are in development. For BD teams, the key question is whether berobenatide's dosing schedule alone can carve out meaningful market share, or whether the drug will need combination strategies—such as pairing with an oral GLP-1 or an amylin analog—to compete on total weight loss. Investors should monitor the timeline for Phase 3 initiation, which will be the next major catalyst for the program and for Pfizer's broader metabolic disease strategy.
Frequently Asked Questions
Why did Pfizer stop the weight loss pill?
Pfizer halted development of the once-daily oral danuglipron in April 2025 after a participant in a clinical trial showed signs of possible liver injury. The company stated the injury resolved after the individual stopped taking the drug, as reported by the Associated Press.
When will the Pfizer weight loss pill be available?
Pfizer is no longer developing an oral weight loss pill. The company's lead obesity asset is now berobenatide, an injectable GLP-1 RA. A timeline for potential availability depends on successful Phase 3 trials and regulatory review, which could take several years.
What is MET097?
MET097 (now called berobenatide) is an ultra-long-acting GLP-1 receptor agonist originally developed by Metsera. Pfizer acquired the asset through its acquisition of the biotech. It is designed for monthly subcutaneous dosing, which differentiates it from weekly GLP-1 competitors.
What is the VESPER-3 trial?
VESPER-3 is a Phase 2b clinical trial evaluating monthly subcutaneous dosing of berobenatide in adults with obesity or overweight. The study met its primary endpoint, showing statistically significant weight loss at week 28 with a safety profile consistent with the GLP-1 class, according to Pfizer's press release.
IntelligenceStrategic Takeaways
Pfizer's berobenatide (formerly MET097) demonstrated continuous weight loss through 28 weeks with monthly subcutaneous dosing in the VESPER-3 Phase 2b trial, showing no plateau at the data cutoff. The ultra-long-acting GLP-1 receptor agonist was acquired via the Metsera acquisition and is now Pfizer's lead obesity asset after the company halted development of the oral danuglipron program in April 2025. Monthly dosing
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About obesity
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow berobenatide developments
FDA obesity alerts and berobenatide pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 33/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Limited source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…